Compare BIIB & DG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BIIB | DG |
|---|---|---|
| Founded | 1978 | 1939 |
| Country | United States | United States |
| Employees | N/A | 194000 |
| Industry | Biotechnology: Pharmaceutical Preparations | Department/Specialty Retail Stores |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.1B | 26.1B |
| IPO Year | 1996 | 2008 |
| Metric | BIIB | DG |
|---|---|---|
| Price | $183.99 | $118.56 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 28 | 22 |
| Target Price | ★ $197.46 | $139.60 |
| AVG Volume (30 Days) | 829.4K | ★ 3.1M |
| Earning Date | 04-30-2026 | 03-12-2026 |
| Dividend Yield | N/A | ★ 2.01% |
| EPS Growth | N/A | ★ 34.05 |
| EPS | ★ 8.79 | 6.85 |
| Revenue | $9,890,600,000.00 | ★ $42,724,369,000.00 |
| Revenue This Year | N/A | $7.14 |
| Revenue Next Year | N/A | $4.17 |
| P/E Ratio | $20.92 | ★ $17.13 |
| Revenue Growth | 2.22 | ★ 5.20 |
| 52 Week Low | $110.04 | $84.70 |
| 52 Week High | $202.41 | $158.23 |
| Indicator | BIIB | DG |
|---|---|---|
| Relative Strength Index (RSI) | 47.87 | 26.64 |
| Support Level | $181.24 | $116.60 |
| Resistance Level | $184.16 | $153.42 |
| Average True Range (ATR) | 4.91 | 3.75 |
| MACD | -0.06 | -0.89 |
| Stochastic Oscillator | 59.95 | 3.92 |
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
Since its beginning in 1939, Dollar General has grown to become the largest dollar store operator in the United States, with more than 20,000 small-box discount stores across 48 states. The firm generated $40 billion in fiscal 2024 sales. The retailer maintains a heavy concentration of stores in rural and low-income markets underserved by big-box retailers. It's 11,000 stock-keeping units, including 2,000 priced at $1 or less, span consumables (82% of sales), seasonal items (10%), home products (5%), and apparel (3%). More than 20% of sales are derived from private label.